SE2351358A1 - Composition for preventing rheumatoid arthritis, preparation method therefor, and application thereof - Google Patents
Composition for preventing rheumatoid arthritis, preparation method therefor, and application thereofInfo
- Publication number
- SE2351358A1 SE2351358A1 SE2351358A SE2351358A SE2351358A1 SE 2351358 A1 SE2351358 A1 SE 2351358A1 SE 2351358 A SE2351358 A SE 2351358A SE 2351358 A SE2351358 A SE 2351358A SE 2351358 A1 SE2351358 A1 SE 2351358A1
- Authority
- SE
- Sweden
- Prior art keywords
- parts
- composition
- rheumatoid arthritis
- preventing
- radix
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract 12
- 238000002360 preparation method Methods 0.000 title claims abstract 9
- 239000003814 drug Substances 0.000 claims abstract description 13
- 241000218671 Ephedra Species 0.000 claims abstract description 4
- 239000009636 Huang Qi Substances 0.000 claims abstract 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000002994 raw material Substances 0.000 claims abstract 3
- 210000000582 semen Anatomy 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 229940124532 absorption promoter Drugs 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000008595 infiltration Effects 0.000 abstract description 6
- 238000001764 infiltration Methods 0.000 abstract description 6
- 210000000988 bone and bone Anatomy 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 241000030538 Thecla Species 0.000 abstract description 4
- 210000000845 cartilage Anatomy 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 210000005222 synovial tissue Anatomy 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010023232 Joint swelling Diseases 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000011552 rat model Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention belongs to the field of traditional Chinese medicine, in particular to a composition for preventing rheumatoid arthritis, as well as a preparation method and an application thereof. The composition for preventing the rheumatoid arthritis according to the present invention is prepared from the following raw material components in parts by mass: 15 to 60 parts of raw Semen Coicis, 5 to 30 parts of Radix Angelicae Sinensis, 5 to 30 parts of Radix Paeoniae Alba, 1 to 15 parts of Herba Ephedra, 5 to 30 parts of Ramulus Cinnamomi, 5 to 30 parts of Radix Glycyrrhizae Preparata, 5 to 30 parts of Rhizoma Atractylodis and 10 to 60 parts of Radix Astragali. CIA rat model experiments have proved that the composition for preventing the rheumatoid arthritis can obviously relieve ankle swelling degrees of CLA rats, X-ray shows that the composition can improve bone destruction, and a pathological section shows that the composition has good effects of inhibiting synovial tissue proliferation, reducing inflammatory cell infiltration and delaying bone and cartilage destruction. The composition has the efficacy of improving symptoms, protecting bones and resisting inflammation on the CLA rats.
Description
id="p-40" id="p-40"
id="p-40"
[0040] FÉG. il shows. HE pathoiogiczti images of arihies of the rats in each group of the experirnentai part of the CIA rats after treatment a.f_tcor id="p-41" id="p-41"
id="p-41"
[0041] Fitlšs. 12 and 13 are charts of anti-CC? antibodies and their changes before and after treatment of chniatæti experiment patients according to the [aresent iiivention; id="p-42" id="p-42"
id="p-42"
[0042] EÉGS. 14 and 15 are charts of 1%' titers and tiieii' changes before and after treatment of the eiinicai experiment patients according to the present iriveritiori; id="p-43" id="p-43"
id="p-43"
[0043] FïGs. 'io and 17 are charts tifhsCRP titers and their changes before an d after "treatment of the ciinicai experiment patients arccoriiiiig to tiie [aresent iiivention; and id="p-44" id="p-44"
id="p-44"
[0044] Flfšs. 18 and 19 are charts ofESiš titers and tiieir changes before and after treatment of the ciinicai experiment patients according to the present irweritifiri.
DETAILED DESCRIPTION id="p-45" id="p-45"
id="p-45"
[0045] The present inveritifiii afiii be further described below in coniuiictioii with the specific exarnpies. id="p-46" id="p-46"
id="p-46"
[0046] Exæirnpie i id="p-47" id="p-47"
id="p-47"
[0047] A traditionai Chinese medicine tiecoctioii for preventing rheuniatoid arthritis in this exarnpie is prepared from the tfoiiotviiig coniponents: 30 g of raw Sernen Coicis, 10 g of Raciix Angeiicae Sinensis, 10 g of Rfadix Paeoniae fftiha, 3 g f>f ifierha Ephedra, 10 g of Rarnuius Cfnnarnonii, 15 g of Radix Giytrjyfrriiiziie iïreparata, 15 g of Riiiztinia, Atractyiodis and 30 g of Radix ffistragaii. id="p-48" id="p-48"
id="p-48"
[0048] The traditional Clhiriese rnediciiie iiecrietiiin in this exarnpie is prepared hy the fiäiioiwirig niethiiii: id="p-49" id="p-49"
id="p-49"
[0049] vaeighing the raw niateriais according to a. vreight ratio; criisiiing, sieving and ntixirig the raw niateriais respectiveiy to obtain a cornprisitifin for preventing rheiiniatfiid arthritis; decoctirig the resuiting cornpivsitiiin for preventing the rhenrnattäid arthritis vvfith 3900 niL of ioriizeti Water for of) niin; rernoviiig drogs and cfantrifiiging to obtain a wifater extract; and pinftirifniiig rotary evaporaticwii on the tifater extract to obtain 150 rnL of a. sointiciii, rianieiy, the decoction, id="p-50" id="p-50"
id="p-50"
[0050] it should be noted tiiat the preparatitvn rrietiiiiii of the ahove traditionai Chiriese rriedicirie decoction is iiinstratitfe oniy, and is not interideci to iimit tiie protection strope of the present iiiventiciri. Of course, the traditional tliiinese inediciiie decoction niay aiso be prepared using a technoiogßf tisuaiiy used in this art, »which tifiii not he ennnierated herein. id="p-51" id="p-51"
id="p-51"
[0051] ifiereiritttter, in order to explore prevention and treattnerit effects of the cornpivsittirtn for preventing the ifhenniatoid arthritis on the rheuniattiiiii arthritis, coiiatgtfii .ii (Colt iijßintiuceii aithritis (CL/Ä) rat rnodei experiinents and ciinicai experiinents Were carried ont, id="p-52" id="p-52"
id="p-52"
[0052] i. Rai irioiiei experirnerrt of eoiiagen Ii (Cfoi Hj-iririiieeii arthritis (CIA) id="p-53" id="p-53"
id="p-53"
[0053] 1t Experimental suhjects id="p-54" id="p-54"
id="p-54"
[0054] Foriy êt-tteek-fild feinale SPF -level iiealtliy ïfliistai' rats each having a body iveight of 180 to 220 g vivere randomiy iiivideti iiito 4- groups: a. norrniti group, a ClA rnodei group, a nfiethritrexa e (íhfftffX) grotip, and a eoirrposition group: vifitii líl rats in each group. id="p-55" id="p-55"
id="p-55"
[0055] 2. hiodeliiig niethfld and administration id="p-56" id="p-56"
id="p-56"
[0056] lïxeept for "the normal group, a rat rnodel of arthritis vtfas ezstalilisireti 'ny iriduoirig tvith bovine eollagen ll in the other groups, respeetivtßly: A speeitie inodeiing method vvas as follows: bovine collagen ll (Lot: 20021, ífiicwiidrex, LlSi/ä) and an ineomplete Freunrgfs adjuvarit (Lot: 7092, (Éhonclrex, LlSJ-t) vvere niixetl and eniulsilied according to a tfoltinie ratio of 1:1, and the rnixture vvas hrmiogenizieti nfitli a ltoniogerlizer (IKA Tlüfš, Gerinaityf) for 30 niin to obtain a iiornogfziiate. The rates tflzere anesthetized ivitli ehloral hydrate vvith a. volume fraetion of 10% on the first tlajy", and then each of the rats tfvas iiij eeled stiheutaneously vvith 200 ug of the iiomogenate in a pluraiity of points at its tail arid elatvs; each of the rats tvas subjeeteri to horister iirimuriizatiivri (lÛÜ rig/rat) once on the 8:3* day; a rat mod ei of coilagen ll-induoed aithritis (fiir-Ä) vvas obtained after nitwdeliiig for a. total of 14 tlays; and the rats nfere administraterl eontintiriusly for 35 days at the hegiiiiiing of the 15* day on the basis of this (IÉEA rnodel, The experimental clesigri flow »vas shown in FIG. l. [0057] The ttontposition, group Was adrniiiistrateci wfitli the traditional Chinese ntedieine titäeotïtion of Example l, a riaily administration dose ooriverted into a clinical equivalent dose of l2.3 g/kg, and a daily gavage tvas given. The nietliotrexate (glvlTX) group tvas administrated twfith niethritrexate, an administration dose was eonverted to a clinical equivalent dose ot' l.()2 ring/kg, and a gaifzige. Was given twfitte a Week., 'lfhe rats in the normal group and the ClA rnodei group vvere atlministrafred hy tlailjvf gavfage With normal saiine. An administration cycle intas 35 days. "fire drug interventions (all converted to clinical doses) in the respective groups vvere shown in Table l: Table l Drug interventions of respective groups Groups Number of Modeling Administration animals Nomial group 10 No Normal saline CIA model group 10 CIA model Normal saline Methotrexate group 10 CIA model MTX (l.02 mg/kg/twice a Week) Composition group 10 CIA model Traditional Chinese medicine decoction in Example l (12.3g/kg/d) id="p-58" id="p-58"
id="p-58"
[0058] Ort the Stf" clay of the experiment, the ortrnprisitirøn group was compared with tiie norrnal group, the ClA model group and the nietitritrexzttcä group. 'lfhcä swiellin g degrees of ltindfoot arikicës, X--ray imageologieal change of hind limhs, ankle pathoiogieal sections, expressioii levels of serum intianirnatorïf' eytoirine tninor neerosis factors o. (TNF-ou) and interienkin iii (iÛL-i ti) as irveii as spieen and tifiynfius eoefticicfrits tvere trhserwfeit. id="p-59" id="p-59"
id="p-59"
[0059] 3. Experimental resuits id="p-60" id="p-60"
id="p-60"
[0060] (i) Botiy weight, thyntns eriefíieiertt, and spieerr coefticierrt id="p-61" id="p-61"
id="p-61"
[0061] The trenrts of changes in hmty weigirts of the rats in 'ttie respective groups tvere shotvn in Fïíš. 2. the eontprtrison of spieen iritiexcfs Was shot/vn in FIG, 3, and the comparison of tifoyrotts inriexes shown in FlG. 4. its ean he seen front FíG. 2 to P16. 4, threre tvere no statistical differences (P>0.(}5) in the hfody Weights, the thynius efieftieients and the spieen eoeiiíieierits antong the grotips. ít nfas indieatert that the rtraditirvnai Chinese rnedieirre eonrposition according to the prfzsfznt inventioti hatt no significant efffcet on the body vveights, the ttißfrnus eoeffieients and the spieen coeftieients of the (IIA rats. id="p-62" id="p-62"
id="p-62"
[0062] (2) Ankie sxveiiirrg degree id="p-63" id="p-63"
id="p-63"
[0063] 'The tnertsurenient results of ankte swffiling degrees of the rats in the respective groups nfere shotvri in HG. S, and the changes in ankie sweiiing riegrees before and after artnrinistratiori *were shown in HG. o. As can he seen tron: FIG. 5, the arikie stvethitg degree of each rat in the rnortei grottp was increased si gniíi earitify atfter one vveek of treatment erirnpared xvith the rather three groups. .As can he seen fiforn FIG. o, after one nionth oftrezttrfnent, the ankie sweiiing degrees of the coinpfisition group and the rnethotrexate grotip v-vere cieereased signitieantlyf (P<Ü.(}5) compared nfith the rnottei group, »xfhieti showen titat the traditionat Chinese rnettieiite crintpositioit aeeorttirrg to the present inveittitrn tftiuirt signritieaiitiy' iniprove the airkie sweiiing degree of the CIA rats. [0064] (S) Seruin intiannnation inriíeatcvrs id="p-65" id="p-65"
id="p-65"
[0065] The analysis of sernnt -oa results of the rats in the respective groups aiter treatment *were shown in HG. 7. .Ås can he seen from FIG. the serum TNF-o: level in the CIA rnodei group was signifiteantty' inerfzztsed (tïnïíiíšfi) tmnfopared ufith the normal grotip. After rhug trtfatinent, the serum "fNF--tt expressions ot* the rats in the eornposition group anti the rnethotrexate group 'øaere signíiiearrtlyf deereased (p<ï0.Û5). it eouid he *tittat the erinrprtsitirtit according *to the present invention tiad a significztnt doxvxi~regrthttirfrg effect on the serum "i'NP'~r;r. levels of the CÅIA rats, ofhieir showert that the cornpaasition according to the present invention itatt a. signifreaiit anti-iriflantinatory effect. id="p-66" id="p-66"
id="p-66"
[0066] The arraiysis of serum IL-l Ei restihs of rats in *the respective groups after treatrrrent x 'as shown/in in FIG. S, As een the seen frorn PÜIG. 8. the serum Iifíß ievei in the CIA ntotíei group Was sigriiñcantiy increased (p<0.()5) coinparert *with the norinai group. rätter' :ting treatinent, the sennn íífiß expressntits in the eornpositioit group and the nrethotrexate group were sigititieantiy dee easeri (pKGIJfí). it itouid he seen that the eoinposition according to the present inventirrri hart a significant tltcavn-regulating eftiect on the serum lL-lti levels tifthe (ÉIA rats, »vhicii siten/ed that the contpositioit according to th.e present invention had a, significant rtnti-inftantinattrrfy rfffertt. [0067] (4) Stafeliiitg of rat foot pads, inflantinatcwijtf cell infiltration, joint tlestiuction and other cases id="p-68" id="p-68"
id="p-68"
[0068] Typical rthotos of article stxfelllrtg after treatment in "the respective groups tvere shotvn in FtG. 9, As can he seen from FÉG. 9, after one inonth of treatment, the foot svvelting degrees of the CIA rats in the cornposition group Were reduced compared tafitlt that in the rnotlei group. lt indicated that the traditional Citinese medicine cornposition according to the present inventioit ctnrld alieviate the foot stfveihng of the ClA rats. id="p-69" id="p-69"
id="p-69"
[0069] X-ray photos of the ankies of the rats in the respective groups a.fter treatrrtfzttt vvere slttnvn in Fifi. lt). In FEÅG. lt), a part circietl hy a sinail red circle sliotvedjoirtt hone destruction, and a part circied "ny a large yellow circle shotwed toot pad snfellirtg. As can be seen tfront FIG. lt), after one rnonth of treatment, the foot pad stvellittg degree and the joint destruction degree of the CIA rats in the coinposition group vvere alleviateti compared tvith those in the model grottp. lt tafas indicated that the traditional Chinese ntedicine cornptisititiit according to the present inventiott could allevizite tlrot [vad swelling, joint tiestrtrction and other cases att" the 'IÅIA rats. id="p-70" id="p-70"
id="p-70"
[0070] 'lífhe histopzrthologitral analysis of the aiitkles of the rats in the respective groups after treatment were shown in FIG. i t, fits can he seen frorn Flíi. ll, cornparetl tafitit the norrnal grouttw, the rats in CIA rrtotiet group had retlected the disappearartce of artieuiar strrtaces, infiltration of ntuititfiie inflrtrnntattiitjt' cells in rtrticrilrtr eavities, syhoviat ityperplasia, artd severe inflarrnnatoty' cell infiltration of connective tissues. The rats in cornposition group had relatively' clean aiticular' cavities, signiiicantly' intrtrosfecl intiantinatory infiltration and other cases, as tvell as itnproved s ynoviai ltytterplttsia, lt wfas iridicaterl that the traditional Chinese rnedicirte eornpositiori :recording to the present invention had the effects of itnprrtvittg the proliferatittir of ankte synovial tissues, redtrcing the infiltration of inflatnrnatory' cells, and delayittg the hone and cartilage destruction in the *LTL/ft rats, id="p-71" id="p-71"
id="p-71"
[0071] Concšusion: the eontpositioti for preventing rheurrrrttoid arthritis according to the present iriventicttt can tihviotasly' aileviate ankle sttfeliiitg degrees of the (CIA rats, X--ray shows that the contpositiort can itnprove bone destruction, and the pathological section shows that the contpositittit has good etffects of initihicting synoviztl tissue proliferatitwrt, reducing inflatrintatttry' ceti infiitifatioit and rielztyiitg bone and cartilrrge rtestnrctionr The rfotnposition :van signifieantly' reduce extaressicwrt levels of infiarnntattoify' cjytokines "fNF--tr and lL--lß in serum of the (EA rats. The contpositirttt has the et"ticacy of irnproving syrrtptrvrtts, gtrotectirtg iJortes and resistirig infianttn ation on the CïA rats. id="p-72" id="p-72"
id="p-72"
[0072] Il. Clinical experintents id="p-73" id="p-73"
id="p-73"
[0073] The tractitiortal Chinese ntedioine decftotittrt in Exarnpie 1 of the present irwentiorr was administfzred vvith one ttose pfzr day, and earth ttose of E50 nïd., was divided irtto two parts for vvarm a/drnittistratiorít, twice a ttay, *with a treatrnent cycïe ofó months. id="p-74" id="p-74"
id="p-74"
[0074] Experitnentai resuhs are as tïoítowvs: id="p-75" id="p-75"
id="p-75"
[0075] FïGs. 12 and 13 are charts 'of arni-tfiftfí? antibotiies and "ttreir changes before :and after treatrn ent. On the nrïftoše, after 24 xvefzks of trffattnent, ali proportiotts of high titers wrote decreased arnong (TCP antihotíy titers of patients, and an overall antíhodyf reduction rate Was 56594» (P>0.t)5). id="p-76" id="p-76"
id="p-76"
[0076] Fíïšs. 14 and 15 are charts of RF titers and their changes before and after treatment. .f-Xs can he seen trotn the figures, a proportion of tweratï RF titers in the patients was not changed rnnch, and a decrtfatse rate of RF wwas 66137945 (JPÅÅOS) after '_24- wtæeks of treatntent. [007 7] Fïíšs. 16 and 17 are charts of hstIÉRP titers and their charages before and after treatment. ffts can he seen from the tïgures, after 24 weeks of treattntent, the hsCRP *was ttecreetseti hy 45% (Pfeütšâ), and an twerait titer proportion »vas not changed rnucït. id="p-78" id="p-78"
id="p-78"
[0078] FïGs. 18 and 19 are charts of ESR titers and their before and after treatment. As can be seen front the 'ñgttreg after 24 weeks oftreatrnent, an ESR reduction rate 44945 (P>0.05), and an oxerat] titer proportion was not changed ntuch. id="p-79" id="p-79"
id="p-79"
[0079] fn surnrnatftf, tlfte eomposition for preventirtg the rtitetsnïtattvid arthritis of the present ítwention ttas pfttentiai effects of reducing (DCP arrtibodies, RF, hsCRP and ESR, and has a ptutential joint protection eftect.
Claims (8)
1.l. A composition for preventing rheumatoid arthritis, wherein the composition is prepared from the following raw material components in parts by mass: 15 to 60 parts of raw Semen Coicis, 5 to 30 parts of Radix Angelicae Sinensis, 5 to 30 parts of Radix Paeoniae Alba, 1 to l5 parts of Herba Ephedra, 5 to 30 parts of Ramulus Cinnamomi, 5 to 30 parts of Radix Glycyrrhizae Preparata, 5 to 30 parts of Rhizoma Atractylodis and 10 to 60 parts of Radix Astragali.
2. The composition for preventing the rheumatoid arthritis according to claim l, wherein the composition is prepared from the following raw material components in parts by mass: 30 parts of raw Semen Coicis, 10 parts of Radix Angelicae Sinensis, l0 parts of Radix Paeoniae Alba, 3 parts of Herba Ephedra, l0 parts of Ramulus Cinnamomi, l5 parts of Radix Glycyrrhizae Preparata, l5 parts of Rhizoma Atractylodis and 30 parts of Radix Astragali.
3. A method for preparing the composition for preventing the rheumatoid arthritis according to claim l or 2, wherein the composition for preventing the rheumatoid arthritis is obtained by crushing, sieving and mixing the components respectively.
4. An application of the composition for preventing the rheumatoid arthritis according to claim l or 2 in the preparation of a drug for preventing and/or treating the rheumatoid arthritis.
5. A traditional Chinese medicine preparation, wherein the traditional Chinese medicine preparation uses the composition for preventing the rheumatoid arthritis according to claim l or 2 as an effective constituent.
6. The traditional Chinese medicine preparation according to claim 5, further comprising the medically acceptable accessory.
7. The traditional Chinese medicine preparation according to claim 6, wherein the accessory is at least one of a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, an adsorption carrier, a surfactant and a lubricant.
8. An application of the traditional Chinese medicine preparation according to any one of claims 5 to 7 in the preparation of a drug for preventing and/ or treating the rheumatoid arthritis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110458037.9A CN113134064A (en) | 2021-04-27 | 2021-04-27 | Composition for preventing rheumatoid arthritis and preparation method and application thereof |
| PCT/CN2021/111561 WO2022227331A1 (en) | 2021-04-27 | 2021-08-09 | Composition for preventing rheumatoid arthritis, preparation method therefor, and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE2351358A1 true SE2351358A1 (en) | 2024-01-23 |
Family
ID=76812270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE2351358A SE2351358A1 (en) | 2021-04-27 | 2021-08-09 | Composition for preventing rheumatoid arthritis, preparation method therefor, and application thereof |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN113134064A (en) |
| SE (1) | SE2351358A1 (en) |
| WO (1) | WO2022227331A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113134064A (en) * | 2021-04-27 | 2021-07-20 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Composition for preventing rheumatoid arthritis and preparation method and application thereof |
| CN114588242B (en) * | 2022-04-15 | 2023-08-01 | 重庆市中医院 | Pharmaceutical composition for treating rheumatoid arthritis |
| CN115814048A (en) * | 2022-12-09 | 2023-03-21 | 北京马家一绝中医风湿骨病研究院 | Chinese medicine for treating rheumatism and its preparation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101321754B1 (en) * | 2013-03-29 | 2013-10-28 | 유한회사한풍제약 | A composition for treating rheumatoid arthritis and osteoarthritis |
| CN103705894B (en) * | 2013-12-24 | 2016-04-20 | 李媛春 | A kind of Chinese medicine decoction for the treatment of rheumatic arthritis |
| CN108514598B (en) * | 2018-04-02 | 2021-08-17 | 黄清春 | Composition for preventing and/or treating rheumatoid arthritis and preparation and application thereof |
| CN108578606B (en) * | 2018-08-01 | 2021-02-19 | 大连医科大学 | Traditional Chinese medicine preparation for treating rheumatoid arthritis |
| CN113134064A (en) * | 2021-04-27 | 2021-07-20 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Composition for preventing rheumatoid arthritis and preparation method and application thereof |
-
2021
- 2021-04-27 CN CN202110458037.9A patent/CN113134064A/en active Pending
- 2021-08-09 SE SE2351358A patent/SE2351358A1/en unknown
- 2021-08-09 WO PCT/CN2021/111561 patent/WO2022227331A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN113134064A (en) | 2021-07-20 |
| WO2022227331A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE2351358A1 (en) | Composition for preventing rheumatoid arthritis, preparation method therefor, and application thereof | |
| CN110585351A (en) | External-use bone-setting ointment and preparation method thereof | |
| CN103285202A (en) | Drug for treating rheumatism | |
| CN110624040A (en) | Pharmaceutical preparation for treating fracture injury at middle stage and preparation method thereof | |
| WO2021203146A1 (en) | Pain-relieving and anti-inflammatory preparation for preventing and treating thrombosis | |
| SE2351359A1 (en) | Composition for preventing and/or treating rheumatoid arthritis, preparation method therefor, and application thereof | |
| SE2351357A1 (en) | Composition for preventing and/or treating rheumatoid arthritis, preparation method therefor, and application thereof | |
| CN104161823A (en) | Traditional Chinese medicine for treating aseptic necrosis of femoral head | |
| CN103623172A (en) | Antithrombotic traditional Chinese medicine formula | |
| CN114432375A (en) | Traditional Chinese medicine composition for treating plateau pulmonary hypertension | |
| CN111991548A (en) | Anti-tumor traditional Chinese medicine composition and preparation method thereof | |
| CN104857441A (en) | Oral preparation for treating femoral head necrosis and preparation method of oral preparation | |
| CN108926705A (en) | A kind of pharmaceutical composition and the preparation method and application thereof for treating rheumatic spur strain | |
| CN1055242C (en) | Chinese medicine for curing aseptic necrosis of head of femur | |
| CN117959371A (en) | Medicine for treating or assisting in treating orthopaedics disease | |
| CN104274640B (en) | A kind of Chinese medicine composition for the treatment of qi stagnation and blood stasis type femur head necrosis | |
| CN1048631C (en) | Medicinal pellet or powder for curing osteoporosis | |
| CN105327279A (en) | Traditional Chinese medicinal composition for treating leukemia | |
| CN114681551B (en) | Traditional Chinese medicine composition for treating arthralgia and myalgia, preparation and application thereof | |
| CN111743965B (en) | A medicine for treating hemorrhoid and ulcer with regenerated silicon | |
| CN108567926B (en) | Traditional Chinese medicine composition for treating blood stasis collateral blocking type autoimmune hepatitis and preparation method thereof | |
| CN105853768A (en) | Traditional Chinese medicine formula for treating rheumatoid arthritis and preparing method and application thereof | |
| CN110960660A (en) | Traditional Chinese medicine plaster for dredging collaterals and removing stasis and preparation method thereof | |
| CN1079161A (en) | Medicine powder " Qushizhitongsan " for eliminating wetness-evil in body and analgesic | |
| CN116549586A (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof |